I hear you. And I'm sure the inclination to just s
Post# of 148282
However, isn't it possible that another government's health regulatory agency might have a slightly lower standard for approval?
And perhaps more important, in the event that we cannot prove statistical significance now, isn't it possible that it will be even more difficult to prove it after another 120 patients—all of whom have received a superior standard of care compared to those who were treated at the beginning of the study.
Bluntly, the more deaths, the greater the statistical significance.
My biggest concern is that having to enroll the full trial is going to take a long time—a time during which the company will presumably not have many catalysts. I remain optimistic for the cd12 results.